Evidence map›Paper›PMID 37297008›Full record

ArticleCancers2023

Follicular Helper and Regulatory T Cells Drive the Development of Spontaneous Epstein-Barr Virus Lymphoproliferative Disorder.

Elshafa Hassan Ahmed, Mark Lustberg, Claire Hale, Shelby Sloan, Charlene Mao, Xiaoli Zhang, Hatice Gulcin Ozer, Sarah Schlotter, Porsha L Smith, Frankie Jeney and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Humanized Mouse Models of Bacterial Infections.Antibiotics (Basel, Switzerland) · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Elshafa Hassan AhmedComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Mark LustbergDivision of Infectious Disease, Department of Internal Medicine, Yale University, New Haven, CT 06520, USA.
Claire HaleDepartment of Biomedical Engineering, College of Engineering, The Ohio State University, Columbus, OH 43210, USA.
Shelby SloanComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Charlene MaoComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Xiaoli ZhangDepartment of Biomedical Informatics/Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-2495-4568
Hatice Gulcin OzerDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA.
Sarah SchlotterComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Porsha L SmithComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Frankie JeneyComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Wing Keung ChanComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Bonnie K HarringtonCollege of Veterinary Medicine, Michigan State University, East Lansing, MI 48824, USA.
Christoph WeigelDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Eric BrooksComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Haley L KlimaszewskiCollege of Medicine, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0003-0885-0029
Christopher C OakesComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Tamrat AbebeDepartment of Microbiology, Immunology, and Parasitology, School of Medicine Tikur Anbessa Specialized Hospital, College of Health Sciences, Addis Ababa University, Addis Ababa AB1000, Ethiopia.
Muntaser E IbrahimDepartment of Molecular Biology, Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan.
Lapo AlinariComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-8870-4162
Gregory K BehbehaniDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Polina ShindiapinaComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Michael A CaligiuriCity of Hope National Medical Center, Duarte, CA 91010, USA.
Robert A BaiocchiComprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · USCity Of Hope National Medical Center · USMichigan State University · USTikur Anbessa Hospital · ETUniversity of Khartoum · SDYale University · US

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Tumor ImmunologyT32CA090223 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2023
$4.1M
NRSA Training CoreTL1TR002735 · NCATS · OHIO STATE UNIVERSITY · PI BUMGARDNER, GINNY L, KIRSCHNER, LAWRENCE S · 2018 to 2022
$1.3M
Development of Vaccine Strategies to prevent EBV+ Lymphoma in Patients with HIVRC2CA148348 · NCI · OHIO STATE UNIVERSITY · PI BAIOCCHI, ROBERT ALAN · 2009 to 2010
$1000k
American Society of Hematology AWD-108964National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Numbers TL1TR002735 & UL1TR002733National Institute of Health 1RC2CA148348-01National Institute of Health T32CA090223NCATS NIH HHS TL1 TR002735NCATS NIH HHS UL1 TR002733NCI NIH HHS RC2 CA148348NCI NIH HHS T32 CA090223
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is a ubiquitous herpes virus associated with various cancers. EBV establishes latency with life-long persistence in memory B-cells and can reactivate lytic infection placing immunocompromised individuals at risk for EBV-driven lymphoproliferative disorders (EBV-LPD). Despite the ubiquity of EBV, only a small percentage of immunocompromised patients (~20%) develop EBV-LPD. Engraftment of immunodeficient mice with peripheral blood mononuclear cells (PBMCs) from healthy EBV-seropositive donors leads to spontaneous, malignant, human B-cell EBV-LPD. Only about 20% of EBV+ donors induce EBV-LPD in 100% of engrafted mice (High-Incidence, HI), while another 20% of donors never generate EBV-LPD (No-Incidence, NI). Here, we report HI donors to have significantly higher basal T follicular helper (Tfh) and regulatory T-cells (Treg), and depletion of these subsets prevents/delays EBV-LPD. Transcriptomic analysis of CD4+ T cells from ex vivo HI donor PBMC revealed amplified cytokine and inflammatory gene signatures. HI vs. NI donors showed a marked reduction in IFNγ production to EBV latent and lytic antigen stimulation. In addition, we observed abundant myeloid-derived suppressor cells in HI donor PBMC that decreased CTL proliferation in co-cultures with autologous EBV+ lymphoblasts. Our findings identify potential biomarkers that may identify individuals at risk for EBV-LPD and suggest possible strategies for prevention.

Indexed as

CD4+ T helper subsetsEpstein–Barr virus (EBV)Hu-PBL-SCID modelimmunocompromised patientslymphoproliferative disorder (LPD)risk factors

Identifiers

PMID37297008
PMCPMC10252287
OpenAlexW4379527716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.